LISSONI, ANDREA ALBERTO
LISSONI, ANDREA ALBERTO
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Fertility outcomes in stage I ovarian immature teratomas
2024 Marino, G; Grassi, T; De Ponti, E; Testa, F; Negri, S; Giuliani, D; Seca, M; Bombelli, M; Santagati, A; Bertoni, M; Jaconi, M; Bonazzi, C; Lissoni, A; Landoni, F; Fruscio, R
Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy
2024 Marino, G; Grassi, T; De Ponti, E; Negri, S; Testa, F; Giuliani, D; Delle Marchette, M; Dell'Oro, C; Fumagalli, D; Donatiello, G; Besana, G; Marchetta, L; Bonazzi, C; Lissoni, A; Landoni, F; Fruscio, R
The paradigm shift in advanced ovarian cancer: Outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis
2024 Bianchi, T; Grassi, T; Bazzurini, L; Testa, F; Corti, J; Pecis Cavagna, G; Bombelli, M; Lissoni, A; Di Martino, G; Trezzi, G; De Ponti, E; Fruscio, R; Landoni, F
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective
2023 Cordani, N; Bianchi, T; Ammoni, L; Cortinovis, D; Cazzaniga, M; Lissoni, A; Landoni, F; Canova, S
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study
2023 Colombo, N; Gadducci, A; Landoni, F; Lorusso, D; Sabbatini, R; Artioli, G; Berardi, R; Ceccherini, R; Cecere, S; Cormio, G; De Angelis, C; Legge, F; Lissoni, A; Mammoliti, S; Mangili, G; Naglieri, E; Petrella, M; Ricciardi, G; Ronzino, G; Salutari, V; Sambataro, D; Savarese, A; Scandurra, G; Tasca, G; Tomao, F; Valabrega, G; Zavallone, L; Pignata, S
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience
2022 Adorni, M; Bazzurini, L; Lissoni, A; Vecchione, F; Negri, S; Grassi, T; Buda, A; Landoni, F
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer
2022 Colombo, N; Tomao, F; Benedetti Panici, P; Nicoletto, M; Tognon, G; Bologna, A; Lissoni, A; Decensi, A; Lapresa, M; Mancari, R; Palaia, I; Tasca, G; Tettamanzi, F; Alvisi, M; Rulli, E; Poli, D; Carlucci, L; Torri, V; Fossati, R; Biagioli, E
Response to chemotherapy and Clinical Outcome of Patients with recurrent epithelial ovarian cancer after PARP inhibitor maintenance treatment: a Multicenter retrospective italina Study
2022 Gadducci, A; Cosio, S; Landoni, F; Lissoni, A; Zola, P; Elena Laudani, M; Ardizzoia, A; Gambino and Enrico Sartori, A
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
2021 Daniele, G; Raspagliesi, F; Scambia, G; Pisano, C; Colombo, N; Frezzini, S; Tognon, G; Artioli, G; Gadducci, A; Lauria, R; Ferrero, A; Cinieri, S; De Censi, A; Breda, E; Scollo, P; De Giorgi, U; Lissoni, A; Katsaros, D; Lorusso, D; Salutari, V; Cecere, S; Zaccarelli, E; Nardin, M; Bogani, G; Distefano, M; Greggi, S; Piccirillo, M; Fossati, R; Giannone, G; Arenare, L; Gallo, C; Perrone, F; Pignata, S
Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer: Efficacy on pathological response
2021 DI MARTINO, G; Lissoni, A; Ferrari, D; DI MEO, M; Cosio, S; Gadducci, A; Landoni, F
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers
2021 Ceppi, L; Grassi, T; Galli, F; Buda, A; Aletti, G; Lissoni, A; Adorni, M; Garbi, A; Colombo, N; Bonazzi, C; Landoni, F; Fruscio, R
Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (Stumps) revealed similarities and differences with leiomyomas and leiomyosarcomas
2021 Conconi, D; Redaelli, S; Lissoni, A; Cilibrasi, C; Perego, P; Gautiero, E; Sala, E; Paderno, M; Dalpra, L; Landoni, F; Lavitrano, M; Roversi, G; Bentivegna, A
Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial
2021 Post, C; de Boer, S; Powell, M; Mileshkin, L; Katsaros, D; Bessette, P; Haie-Meder, C; Ottevanger, N; Ledermann, J; Khaw, P; D'Amico, R; Fyles, A; Baron, M; Kitchener, H; Nijman, H; Lutgens, L; Brooks, S; Jürgenliemk-Schulz, I; Feeney, A; Goss, G; Fossati, R; Ghatage, P; Leary, A; Do, V; Lissoni, A; Mccormack, M; Nout, R; Verhoeven-Adema, K; Smit, V; Putter, H; Creutzberg, C
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial
2021 Di Liello, R; Arenare, L; Raspagliesi, F; Scambia, G; Pisano, C; Colombo, N; Frezzini, S; Tognon, G; Artioli, G; Gadducci, A; Lauria, R; Ferrero, A; Cinieri, S; De Censi, A; Breda, E; Scollo, P; De Giorgi, U; Lissoni, A; Katsaros, D; Lorusso, D; Salutari, V; Cecere, S; Lapresa, M; Nardin, M; Bogani, G; Distefano, M; Greggi, S; Gargiulo, P; Schettino, C; Gallo, C; Daniele, G; Califano, D; Perrone, F; Pignata, S; Piccirillo, M
Imact of bevacizumab-containing primary treatment on outcome of recurrent ovarian cancer: An Italian study
2020 Gadducci, A; Cosio, S; Lissoni, A; Zizioli, V; Adorni, M; Ferrero, A; Landoni, F; Sartori, E
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel
2020 Lorusso, D; Bologna, A; Cecere, S; De Matteis, E; Scandurra, G; Zamagni, C; Arcangeli, V; Artioli, F; Bella, M; Blanco, G; Cardalesi, C; Casartelli, C; De Vivo, R; Di Napoli, M; Gisone, E; Lauria, R; Lissoni, A; Loizzi, V; Maccaroni, E; Mangili, G; Marchetti, C; Martella, F; Naglieri, E; Parolin, V; Ricciardi, G; Ronzino, G; Salutari, V; Scarfone, G; Secondino, S; Spagnoletti, I; Tasca, G; Tognon, G; Guarneri, V
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
2019 de Boer, S; Powell, M; Mileshkin, L; Katsaros, D; Bessette, P; Haie-Meder, C; Ottevanger, P; Ledermann, J; Khaw, P; D'Amico, R; Fyles, A; Baron, M; Jurgenliemk-Schulz, I; Kitchener, H; Nijman, H; Wilson, G; Brooks, S; Gribaudo, S; Provencher, D; Hanzen, C; Kruitwagen, R; Smit, V; Singh, N; Do, V; Lissoni, A; Nout, R; Feeney, A; Verhoeven-Adema, K; Putter, H; Creutzberg, C; Mccormack, M; Whitmarsh, K; Allerton, R; Gregory, D; Symonds, P; Hoskin, P; Adusumalli, M; Anand, A; Wade, R; Stewart, A; Taylor, W; Lutgens, L; Hollema, H; Pras, E; Snyers, A; Westerveld, G; Jobsen, J; Slot, A; Mens, J; Stam, T; Van Triest, B; Van der Steen-Banasik, E; De Winter, K; Quinn, M; Kolodziej, I; Pyman, J; Johnson, C; Capp, A; Fossati, R; Colombo, A; Carinelli, S; Ferrero, A; Artioli, G; Davidson, C; Mclachlin, C; Ghatage, P; Rittenberg, P; Souhami, L; Thomas, G; Duvillard, P; Berton-Rigaud, D; Tubiana-Mathieu, N
Clinical outcome of patients with malignant tumors associated with mature cystic teratomas of the ovary: A retrospective multicenter Italian study
2019 Gadducci, A; Giuliani, D; Cosio, S; Lissoni, A; Ferrero, A; Landoni, F
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
2019 Colombo, N; Zaccarelli, E; Baldoni, A; Frezzini, S; Scambia, G; Palluzzi, E; Tognon, G; Lissoni, A; Rubino, D; Ferrero, A; Farina, G; Negri, E; Pesenti Gritti, A; Galli, F; Biagioli, E; Rulli, E; Poli, D; Gerardi, C; Torri, V; Fossati, R; D'Incalci, M
Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery
2019 DELLE MARCHETTE, M; Ceppi, L; Andreano, A; Bonazzi, C; Buda, A; Grassi, T; Giuliani, D; Sina, F; Lamanna, M; Bianchi, T; Lissoni, A; Landoni, F; Valsecchi, M; Fruscio, R